FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John McCaffrey

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
David G Pfister; John McCaffrey; Andrew J Zahalsky; Gary K Schwartz; Eric Lis; William Gerald; Andrew G Huvos; Jatin P Shah; Dennis H Kraus; Ashok R Shaha; Bhuvanesh Singh; Suzanne L Wolden; Michael J Zelefsky; Ilana Palgi
A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Farhang Rabbani; Joel Sheinfeld; Hesam Farivar-Mohseni; A Leon; M J Rentzepis; Victor E Reuter; Harry W Herr; John McCaffrey; Robert J Motzer; Dean F Bajorin; George J Bosl
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse.
W Kevin Kelly; Tracy Curley; Susan F Slovin; Glenn Heller; John McCaffrey; Dean F Bajorin; A Ciolino; Kevin Regan; Morton K Schwartz; Philip W Kantoff; D George; William K Oh; M Smith; D Kaufman; Eric J Small; Lawrence H Schwartz; Steven M Larson; William Tong; Howard I Scher
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John McCaffrey (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2002: David G Pfister; John McCaffrey; Andrew J Zahalsky; Gary K Schwartz; Eric Lis; William Gerald; Andrew G Huvos; Jatin P Shah; Dennis H Kraus; Ashok R Shaha; Bhuvanesh Singh; Suzanne L Wolden; Michael J Zelefsky; Ilana Palgi
A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Investigational new drugs 2002;20(1):123-7.
2001: Farhang Rabbani; Joel Sheinfeld; Hesam Farivar-Mohseni; A Leon; M J Rentzepis; Victor E Reuter; Harry W Herr; John McCaffrey; Robert J Motzer; Dean F Bajorin; George J Bosl
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2020-5.
2001: W Kevin Kelly; Tracy Curley; Susan F Slovin; Glenn Heller; John McCaffrey; Dean F Bajorin; A Ciolino; Kevin Regan; Morton K Schwartz; Philip W Kantoff; D George; William K Oh; M Smith; D Kaufman; Eric J Small; Lawrence H Schwartz; Steven M Larson; William Tong; Howard I Scher
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(1):44-53.
2000: Jacqueline Vuky; John McCaffrey; Michelle Ginsberg; Tania V Mariani; Dean F Bajorin; George J Bosl; Robert J Motzer
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors.
Investigational new drugs 2000;18(3):265-7.
2000: PM Dodd; John McCaffrey; Madhu Mazumdar; E Icasiano; G Higgins; Harry W Herr; Dean F Bajorin
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma.
Investigational new drugs 2000;18(3):247-51.
2000: Dean F Bajorin; John McCaffrey; PM Dodd; S Hilton; Madhu Mazumdar; W Kevin Kelly; Harry W Herr; Howard I Scher; E Icasiano; G Higgins
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
Cancer 2000;88(7):1671-8.
2000: PM Dodd; John McCaffrey; S Hilton; Madhu Mazumdar; Harry W Herr; W Kevin Kelly; E Icasiano; Mary G Boyle; Dean F Bajorin
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):840-6.
2000: PM Dodd; John McCaffrey; Madhu Mazumdar; Howard I Scher; G Higgins; Mary G Boyle; Harry W Herr; Dean F Bajorin
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer.
Cancer investigation 2000;18(7):626-34.
1999: Dean F Bajorin; PM Dodd; Madhu Mazumdar; Melissa Fazzari; John McCaffrey; Howard I Scher; Harry W Herr; G Higgins; Mary G Boyle
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3173-81.
1999: PM Dodd; John McCaffrey; Harry W Herr; Madhu Mazumdar; Jennifer Bacik; G Higgins; Mary G Boyle; Howard I Scher; Dean F Bajorin
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2546-52.
1999: PM Dodd; John McCaffrey; Madhu Mazumdar; Howard I Scher; V Vlamis; G Higgins; Harry W Herr; Dean F Bajorin
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Cancer 1999;85(5):1145-50.
1998: Dean F Bajorin; John McCaffrey; S Hilton; Madhu Mazumdar; W Kevin Kelly; Howard I Scher; J Spicer; Harry W Herr; G Higgins
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2722-7.
1998: John McCaffrey; Dean F Bajorin
Therapy for good risk germ cell tumors.
Seminars in oncology 1998;25(2):186-93.
1998: WJ Berg; John McCaffrey; Lawrence H Schwartz; Tania V Mariani; Madhu Mazumdar; Robert J Motzer
A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma.
Investigational new drugs 1998;16(4):337-40.
1997: Andrew D Seidman; Clifford Hudis; John McCaffrey; William Tong; Violante E Currie; Mary Ellen Moynahan; Maria Theodoulou-Haber; I Tepler; Marc J Gollub; Larry Norton
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-72-S17-76.
1997: John McCaffrey; Harry W Herr
Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma.
Surgical oncology clinics of North America 1997;6(4):667-81.
1997: John McCaffrey; Dean F Bajorin; Howard I Scher; George J Bosl
Combined-modality therapy for bladder cancer.
Oncology (Williston Park, N.Y.) 1997;11(9 Suppl 9):18-26.
1997: John McCaffrey; Madhu Mazumdar; Dean F Bajorin; George J Bosl; V Vlamis; Robert J Motzer
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2559-63.
1997: John McCaffrey; S Hilton; Madhu Mazumdar; S Sadan; M Heineman; J Hirsch; W Kevin Kelly; Howard I Scher; Dean F Bajorin
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2449-55.
1997: John McCaffrey; S Hilton; Madhu Mazumdar; S Sadan; W Kevin Kelly; Howard I Scher; Dean F Bajorin
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1853-7.